Emyria Obtains TGA Approval for Medical Grade Monitoring App
Released
Released
Announcement PDF
ASX Announcement
12/05/2021
Emyria obtains TGA Approval for medical grade, smartphone
enabled, cardiovascular monitoring software
Highlights:
●
Emyria has received an Australian-first, Class IIa “software-as-a-medical-device”
(SaMD) registration with the Therapeutic Goods Administration (TGA) for a unique
smartphone-based, medical-grade, heart rate (HR), heart rate variability (HRV) and
atrial fibrillation (AF) monitoring application using only a smartphone camera
●
Running on both Apple and Android phones, the medical-grade monitoring tool
opens up further opportunities for Emyria to remotely capture objective health data
for its drug development, telemedicine and consumer healthcare projects
●
Emyria plans to initially use its software platform to capture objective, clinical
measures remotely during these upcoming clinical trials and projects:
●
EMD-003 - pursuing a Schedule 3 registration of a cannabinoid-based medicine
targeting psychological distress [1]
●
EMDMA-001 - An MDMA-assisted psychotherapy trial for post-traumatic stress
disorder (PTSD) [2] and;
●
EDICT - “An advanced digital monitoring and engagement platform for at-risk
and confirmed COVID-19 individuals” - part of the WA Health Grant awarded in
Feb 2021 [3]
●
The successful TGA registration highlights Emyria’s leading position in the
development of Real-World Evidence (RWE) technologies and a commitment to
meeting the highest regulatory standards for new treatments for unmet needs.
Emyria Limited (ASX: EMD) (Emyria or the
Company), a data-backed treatment development
and clinical services company, is pleased to
announce it has achieved a Class IIa
“Software as a Medical Device” registration on
the Australian Register of Therapeutic Goods (ARTG)
from Australia’s Therapeutic Goods Administration
(TGA).
The product is titled “Smartphone camera home
cardiovascular monitoring application software”
(ARTG code: 365211)
1
Emyria’s Managing Director, Dr Michael Winlo, said: “Obtaining this classification
highlights Emyria’s commitment to formal regulatory approval of novel drug treatments
and technologies for unmet clinical needs.
Class IIa registration means Emyria’s Real-World Evidence platforms are now capable of
capturing medical grade vital signs using just an Apple or Android smartphone.
Emyria plans on using this capability in our upcoming drug development programs which
allows our clinical teams to remotely monitor additional safety and efficacy outcomes data
in our trial participants.
We also believe this capability has applications in a variety of medical and consumer health
monitoring settings where medical-grade remote monitoring can improve the care of
patients with complex needs.”
Emyria’s ‘Openly’ RWE technology platform
Openly is Emyria’s remote Real-World Evidence (RWE) technology platform and was initially
developed as a contactless, remote COVID-19 screening and management tool using just a
smartphone. By leveraging the capabilities of an individual’s smartphone, one can overcome
the significant challenges of obtaining, distributing and maintaining stand-alone medical
hardware. (ASX announcement 15 Sep 2020)
With this Class IIa registration, Openly is now recognised as being able to capture
medical-grade measurements of an individual’s heart rate, heart rate variability and atrial
fibrillation status, remotely. When heart rate and heart rate variability change from baseline
it can be a sign of early infection or a physical manifestation of stress or mental distress. [1]
Remotely captured vital sign measurements complement patient-reported outcomes data
by providing objective measures of physiological status. These data can be provided to a
clinician to support clinical management decisions and referral thresholds as well as support
ongoing analysis of the safety and efficacy of novel treatments.
2
Emyria’s leading position in developing Real World Evidence data technology
The TGA assesses medical devices before they can be approved for use in Australia. Devices
must be included on the ARTG before they can be lawfully sold in Australia.
A Class IIa classification applies to software that is intended to provide information used to
make decisions with diagnostic or therapeutic purposes. Successful classification as a Class
IIa device requires passing detailed verification and clinical evaluation procedures and
attracts a higher level of scrutiny.
Manufacturers of Class IIa medical devices must also obtain conformity assessment
certification from an independent body (eg, the TGA) prior to inclusion in the ARTG.
Emyria’s Class IIa classification applies to a unique software development kit (SDK),
developed with technology partner Happitech. The SDK can be incorporated into Emyria’s
smartphone applications and Real-World Evidence platforms. Emyria is the exclusive Sponsor
of this registration and will continue to work with Happitech to develop additional
medical-grade cardiovascular and respiratory monitoring functionality for the platform.
Initial applications and ongoing development
The TGA approval of the expanded functionality of the Openly platform provides a unique
opportunity to remotely monitor patients in clinical studies, provide telehealth services to
patients and enable other consumer healthcare products. Software based medical devices
are rapidly gaining importance as platforms, such as Apple’s HealthKit, extend the accuracy
and utility of expensive, hospital-based medical equipment.
Emyria plans to use Openly to remotely capture objective clinical measures from patient’s
during pivotal and landmark clinical trials and projects in planning. Initially:
○
EMD-003 (targeting psychological distress)
○
EMDMA-001 (targeting PTSD) and;
○
EDICT - “An advanced digital monitoring and engagement platform for at-risk
and confirmed COVID-19 individuals”
Remotely captured vital signs data complements routinely gathered clinical assessment and
patient-reported outcomes measures. Such data can also assist in the development of
companion smartphone apps which, if properly validated and registered, could facilitate
self-care and support for patients, and remote patient monitoring for clinicians, for newly
registered treatments.
This announcement has been approved and authorised by the Board of Emyria Limited.
For further information on Emyria:
Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au
Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au
3
References
[1]
See ASX announcement 07 APR 21
[2]
See ASX announcement 05 MAR 21
[3]
See ASX announcement 05 FEB 21
[4]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900369/
About Emyria (www.emyria.com)
Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target
unmet needs and are focused on obtaining approval from major global regulators. Emyria’s
drug development programs are informed by insights generated from extensive analysis of
Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across
Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au)
Emyria Data provides deep treatment insights and is therefore a source of unique IP,
strategically designed drug development and personalised care programs.
Emyria’s first drug development program, EMD-003 is targeting unmet needs in mental
health. Specifically psychological distress and the symptoms of anxiety, depression and
stress.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company,
the company’s strategy, future operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements.
Actual results may differ materially from those indicated by such forward-looking statements as a
result of various important factors, including: the Company’s ability to successfully develop its product
candidates and timely complete its planned clinical programs and the Company’s ability to obtain
marketing approvals for its product candidates. In addition, the forward-looking statements included
in this press release represents the Company’s views as of the date hereof. The Company anticipates
that subsequent events and developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not
be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
4
Share your feedback
Discover